No Data
No Data
Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials – A Hold Rating Analysis
Borr Drilling, Aehr Test Systems, Airship AI Among Premarket Losers' Pack
Express News | BioXcel Therapeutics Shares Are Trading Lower After the Company Announced a $25 Million Registered Direct Offering
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop tr
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint
Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges
No Data
Nuyoah : 看起来短裤很喜欢这里